The new prostate cancer drug Erleada has landed in general hospitals in Korea.

According to industry sources, Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) has passed the drug committee (DC) review at the Big 5 tertiary hospitals in Korea, - Samsung Medical Center, Seoul National University Hospital, Seoul, Asan Medical Center, Seoul St.Mary’s Hospital, and Sinchon Severance Hospital – and its prescription code has been already inserted into 60 medical institutions nationwide.

The drug has seemingly quickly settled in the prescription market after it was listed for reimbursement in April.

Erleada is an androg